A Case Report on Rare Case of Pancreatic Metastasis from Primary Lung Adenocarcinoma: Treated Through a Non-surgical Approach.

Syed Mohsin Raza, Adeel Riaz, Aqueel Shahid, Tabinda Sadaf
{"title":"A Case Report on Rare Case of Pancreatic Metastasis from Primary Lung Adenocarcinoma: Treated Through a Non-surgical Approach.","authors":"Syed Mohsin Raza,&nbsp;Adeel Riaz,&nbsp;Aqueel Shahid,&nbsp;Tabinda Sadaf","doi":"10.37029/jcas.v9i2.507","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Most frequent sites of metastasis from lung cancer are the liver, brain and adrenal. Pancreas is an infrequent site of solitary metastasis from the lung primary with limited treatment options. There is insufficient data on the prognosis and optimal management of such cases.</p><p><strong>Case description: </strong>We report a case of 44-year-old gentleman diagnosed with locally advanced lung adenocarcinoma Stage T4N3 who was treated radically with chemoradiation therapy, followed by a relapse of solitary pancreatic metastasis, which was treated with targeted therapy, erlotinib, due to the presence of epidermal growth factor receptor (EGFR) mutation.</p><p><strong>Practical implications: </strong>This case reports an excellent radiological and symptomatic response in a patient who received erlotinib for advanced non-small-cell lung cancer (NSCLC). The use of EGFR-tyrosine kinase inhibitors has led to better prognosis and longer progression-free survival for patients with advanced NSCLC. However, the long-term survival of patients with metastatic NSCLC is limited.</p>","PeriodicalId":73631,"journal":{"name":"Journal of cancer & allied specialties","volume":"9 2","pages":"507"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/38/e7/JCAS-9-507.PMC10405981.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of cancer & allied specialties","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37029/jcas.v9i2.507","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Most frequent sites of metastasis from lung cancer are the liver, brain and adrenal. Pancreas is an infrequent site of solitary metastasis from the lung primary with limited treatment options. There is insufficient data on the prognosis and optimal management of such cases.

Case description: We report a case of 44-year-old gentleman diagnosed with locally advanced lung adenocarcinoma Stage T4N3 who was treated radically with chemoradiation therapy, followed by a relapse of solitary pancreatic metastasis, which was treated with targeted therapy, erlotinib, due to the presence of epidermal growth factor receptor (EGFR) mutation.

Practical implications: This case reports an excellent radiological and symptomatic response in a patient who received erlotinib for advanced non-small-cell lung cancer (NSCLC). The use of EGFR-tyrosine kinase inhibitors has led to better prognosis and longer progression-free survival for patients with advanced NSCLC. However, the long-term survival of patients with metastatic NSCLC is limited.

Abstract Image

Abstract Image

Abstract Image

罕见的原发性肺腺癌胰腺转移病例报告:通过非手术方法治疗。
简介:肺癌最常见的转移部位是肝、脑和肾上腺。胰腺是肺原发灶孤立转移的少见部位,治疗选择有限。关于此类病例的预后和最佳处理的数据不足。病例描述:我们报告了一例44岁的男性,被诊断为局部晚期肺腺癌T4N3期,他接受了放化疗的彻底治疗,随后孤立性胰腺转移复发,由于表皮生长因子受体(EGFR)突变的存在,他接受了靶向治疗厄洛替尼的治疗。实际意义:本病例报告了一名接受厄洛替尼治疗晚期非小细胞肺癌(NSCLC)的患者的出色放射学和症状反应。egfr -酪氨酸激酶抑制剂的使用为晚期NSCLC患者带来了更好的预后和更长的无进展生存期。然而,转移性NSCLC患者的长期生存是有限的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信